Cassava pays $40M over allegedly misleading Alzheimer's update
WEB4 days ago · Cassava’s presentation of the data showed a -1.5 change on placebo and up to -5.7 on simufilam. Burns is paying $85,000 to settle her part of the case. Burns is paying $85,000 to settle her part ...
Cassava to Pay $40 Million to SEC Over Alzheimer’s Drug Claims
WEB4 days ago · Drugmaker Cassava Sciences Inc. and two former executives agreed to pay more than $40 million to resolve US Securities and Exchange Commission claims they misled the public about the success of an Alzheimer’s drug trial. Cassava published results in 2020 based on hand-selected data that showed patients’ memories improved, though the …
SEC Charges Cassava Sciences Over Manipulated Alzheimer's Trial …
WEB4 days ago · Alzheimer’s drug developer Cassava Sciences Inc (NASDAQ:SAVA), its founder Remi Barbier, and former Senior VP of Neuroscience Lindsay Burns have agreed to pay over $40 million to resolve SEC ...
Cassava Sciences Resolves SEC Investigation - Yahoo Finance
WEB5 days ago · Advertisement. AUSTIN, Texas, Sept. 26, 2024 (GLOBE NEWSWIRE) -- Cassava Sciences, Inc. (“Cassava” or the “Company”) (Nasdaq: SAVA), a biotechnology company focused on Alzheimer’s ...
Cassava Sciences Shares Lower Premarket on $40M Penalty to …
WEB5 days ago · Cassava, Barbier, and Burns also agreed to pay civil penalties of $40 million, $175,000, and $85,000, respectively, the SEC said. ... Dow Jones Newswires is a market-moving financial and business ...
Cassava Sciences settles SEC charges of ‘misleading
WEB5 days ago · SPX. 0.40%. Shares of Cassava Sciences Inc. dropped more than 12% in the extended session Thursday U.S. securities regulators announced a settlement with the pharma company, after charging it and ...
Executives Depart Cassava, Maker of Disputed Alzheimer’s Drug
WEBJul 18, 2024 · Two top officials at Cassava Sciences — a small pharmaceutical company in Austin, Texas, embroiled in years of controversy over a proposed Alzheimer’s drug — have resigned.
Cassava Sciences Reports Q2 2024 Financial Results and …
WEBAug 8, 2024 · Press Releases. Cassava Sciences Reports Q2 2024 Financial Results and Operational Updates. $207.3 Million in Cash and Cash Equivalents at June 30, 2024. Company in Advanced Discussions to Resolve SEC Investigation. $40 Million Estimated Loss Contingency Recorded in Q2 for Resolution. Conference Webcast Scheduled for Today at 8:30AM ET.
Embattled Alzheimer’s Researcher Is Charged With Fraud
WEBJun 28, 2024 · Simufilam’s manufacturer, Cassava Sciences, a pharmaceutical company based in Texas, has said the drug improves cognition in Alzheimer’s patients.
Cassava Sciences Issues Statement on Former Science Advisor
WEBAUSTIN, Texas, June 28, 2024 (GLOBE NEWSWIRE) -- Cassava Sciences, Inc. (Nasdaq: SAVA), reported it has learned today that a federal grand jury returned an indictment charging Hoau-Yan Wang for allegedly defrauding the U.S. National Institutes of Health (NIH). Hoau-Yan Wang was a tenured medical professor at a public university’s medical school as well as a former paid science advisor to ...